Key result
Arhgef11 loss in salt-sensitive rats lowers BP by ~30 mm Hg and decreases proteinuria.
Why the study?
Arhgef11 was previously implicated in kidney injury in Dahl salt-sensitive rats, but the molecular mechanisms underlying renal protection from Arhgef11 loss remained to be clarified.
Does loss of Arhgef11 reduce proteinuria and blood pressure in Dahl salt-sensitive rats?
Does loss of Arhgef11 reduce proteinuria and blood pressure in Dahl salt-sensitive rats?
Effect estimate: >2-fold lower proteinuria, 30 mm Hg lower BP
Loss of Arhgef11 in Dahl salt-sensitive rats protects against hypertension-induced renal injury and lowers blood pressure by altering actin cytoskeleton-mediated cell morphology and function.
No immediate clinical implications; leaves open Arhgef11 as a therapeutic target in salt-sensitive hypertension.
Arhgef11 is a Rho-guanine nucleotide exchange factor that was previously implicated in kidney injury in the Dahl salt-sensitive (SS) rat, a model of hypertension-related chronic kidney disease. Reduced Arhgef11 expression in an SS- Arhgef11 SHR -minimal congenic strain (spontaneously hypertensive rat allele substituted for S allele) significantly decreased proteinuria, fibrosis, and improved renal hemodynamics, without impacting blood pressure compared with the control SS (SS-wild type). Here, SS- Arhgef11 −/− and SS-wild type rats were placed on either low or elevated salt (0.3% or 2% NaCl) from 4 to 12 weeks of age. On low salt, starting at week 6 and through week 12, SS- Arhgef11 −/− animals demonstrated a 3-fold decrease in proteinuria compared with SS-wild type. On high salt, beginning at week 6, SS- Arhgef11 −/− animals demonstrated >2-fold lower proteinuria from weeks 8 to 12 and 30 mm Hg lower BP compared with SS-wild type. To better understand the molecular mechanisms of the renal protection from loss of Arhgef11 , both RNA sequencing and discovery proteomics were performed on kidneys from week 4 (before onset of renal injury/proteinuria between groups) and at week 12 (low salt). The omics data sets revealed loss of Arhgef11 (SS- Arhgef11 −/− ) initiates early transcriptome/protein changes in the cytoskeleton starting as early as week 4 that impact a number of cellular functions, including actin cytoskeletal regulation, mitochondrial metabolism, and solute carrier transporters. In summary, in vivo phenotyping coupled with a multi-omics approach provides strong evidence that increased Arhgef11 expression in the Dahl SS rat leads to actin cytoskeleton-mediated changes in cell morphology and cell function that promote kidney injury, hypertension, and decline in kidney function.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2020) studied Hypertension-induced renal injury. Arhgef11 knockout (SS-Arhgef11-/-) vs. SS-wild type was evaluated on Proteinuria and blood pressure (>2-fold lower proteinuria, 30 mm Hg lower BP). Loss of Arhgef11 in Dahl salt-sensitive rats decreased proteinuria >2-fold and lowered blood pressure by 30 mm Hg on a high salt diet compared to wild-type controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: